Tags

Type your tag names separated by a space and hit enter

ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.
Clin Nephrol 2012; 77(2):119-25CN

Abstract

BACKGROUND

The efficacy of omega-3 fatty acids (O3FA) in IgA nephropathy remains a controversial issue. The aim of the current updated meta-analysis is to assess the efficacy of O3FA treatment for adult IgA nephropathy.

METHODS

We searched PubMed/MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for randomized controlled trials that compared O3FA treatments with placebo or no treatment in adult IgA nephropathy. Outcomes of interest were effects on urine protein excretion (UPE) and renal function.

RESULTS

Five RCTs (239 patients) were included for analysis. Compared with control groups, O3FA treatments did not show significant benefits for reducing UPE (standardized mean difference (SMD), -0.111; 95% confidence interval (CI), -0.369 - 0.147) or improving glomerular filtration rate (GFR) or estimated GFR (SMD, 0.177; 95% CI, -0.082 - 0.435), although the pooled results slightly favored O3FA. On the other hand, a lower risk of an increase of 50% or more in serum creatinine and ESRD were found in O3FA-treated IgA nephropathy patients (RR 0.189; 95% CI 0.068 - 0.524, p = 0.001; RR 0.236; 95% CI 0.094 - 0.594, p = 0.002), but the two outcomes were reported in only two trials.

CONCLUSION

The current metaanalysis suggests that there are insufficient data to confirm the efficacy of O3FA treatments for proteinuria and renal function in IgA nephropathy. Further large scale trials are needed to shed more light on this issue.

Authors+Show Affiliations

Department of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.No affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22257542

Citation

Liu, Lin-Lin, and Li-Ning Wang. "Ω-3 Fatty Acids Therapy for IgA Nephropathy: a Meta-analysis of Randomized Controlled Trials." Clinical Nephrology, vol. 77, no. 2, 2012, pp. 119-25.
Liu LL, Wang LN. Ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2012;77(2):119-25.
Liu, L. L., & Wang, L. N. (2012). Ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clinical Nephrology, 77(2), pp. 119-25. doi:10.5414/CN107244.
Liu LL, Wang LN. Ω-3 Fatty Acids Therapy for IgA Nephropathy: a Meta-analysis of Randomized Controlled Trials. Clin Nephrol. 2012;77(2):119-25. PubMed PMID: 22257542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. AU - Liu,Lin-Lin, AU - Wang,Li-Ning, PY - 2012/1/20/entrez PY - 2012/1/20/pubmed PY - 2012/4/11/medline SP - 119 EP - 25 JF - Clinical nephrology JO - Clin. Nephrol. VL - 77 IS - 2 N2 - BACKGROUND: The efficacy of omega-3 fatty acids (O3FA) in IgA nephropathy remains a controversial issue. The aim of the current updated meta-analysis is to assess the efficacy of O3FA treatment for adult IgA nephropathy. METHODS: We searched PubMed/MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for randomized controlled trials that compared O3FA treatments with placebo or no treatment in adult IgA nephropathy. Outcomes of interest were effects on urine protein excretion (UPE) and renal function. RESULTS: Five RCTs (239 patients) were included for analysis. Compared with control groups, O3FA treatments did not show significant benefits for reducing UPE (standardized mean difference (SMD), -0.111; 95% confidence interval (CI), -0.369 - 0.147) or improving glomerular filtration rate (GFR) or estimated GFR (SMD, 0.177; 95% CI, -0.082 - 0.435), although the pooled results slightly favored O3FA. On the other hand, a lower risk of an increase of 50% or more in serum creatinine and ESRD were found in O3FA-treated IgA nephropathy patients (RR 0.189; 95% CI 0.068 - 0.524, p = 0.001; RR 0.236; 95% CI 0.094 - 0.594, p = 0.002), but the two outcomes were reported in only two trials. CONCLUSION: The current metaanalysis suggests that there are insufficient data to confirm the efficacy of O3FA treatments for proteinuria and renal function in IgA nephropathy. Further large scale trials are needed to shed more light on this issue. SN - 0301-0430 UR - https://www.unboundmedicine.com/medline/citation/22257542/ω_3_fatty_acids_therapy_for_IgA_nephropathy:_a_meta_analysis_of_randomized_controlled_trials_ L2 - http://www.dustri.com/nc/journals-in-english.html?artId=9392 DB - PRIME DP - Unbound Medicine ER -